Abbott announced the next phase of partnership with the U.S. Department of Defense and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury efforts of its kind.
A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease – via an eye test.
Roche is seeking damages and compensation in a U.S. lawsuit against former executives of a Utah-based company, the Swiss drugmaker’s latest case targeting what the company calls fraudulent schemes involving its diabetes test strips.
Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.
As the United States continues to grapple with the opioid epidemic, researchers have developed a new test that can measure pain biomarkers in the blood.
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and KingMed Diagnostics, a laboratory services leader in China, announced that they have entered into a strategic partnership for the PGDx elioTM tissue complete assay.
With new blood test, Roche dives deeper into personal cancer careBiopsies, Blockbusters, Blood, Blood Tests, Cancer, Diagnostic Tests, DNA, Doctors, Gene Sequencing, Genetic Profiling, Genetics, Genomics, Immunotherapies, Mutations, Non-Small Cell Lung Cancer, Oncologists, Personal Care, Solid Tumors, Tumor Biopsies
Swiss drugmaker Roche upped the company’s bet on personalized cancer treatment and is ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood.
With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.
EpicGenetics and Massachusetts General Hospital are launching a Phase II clinical trial to test a tuberculosis vaccine, CBG, as a potential treatment for fibromyalgia.
Israel’s Medial EarlySign, whose machine-learning based technology is meant to help improve patient management, said on Tuesday it raised $30 million, bringing its total funding to $50 million.